Research map: The association of MASLD, lipoprotein(a) and long-term outcomes: Results from the multi-ethnic study of atherosclerosis

Back to the article

Papers in this map

  1. Multi-Ethnic Study of Atherosclerosis: Objectives and Design · Diane E. Bild · 2002 · 4013 citations · Cited by this paper
  2. The association of MASLD, lipoprotein(a) and long-term outcomes: Response letter · Gomathy Nageswaran · 2026 · Cites this paper
  3. Dynamic regulation of circulating endotrophin by changes in fat mass in humans · 2026 · Related
  4. A multisociety Delphi consensus statement on new fatty liver disease nomenclature · Mary Eugenia Rinella · 2023 · 3201 citations · Cited by this paper
  5. Interpreting lipoprotein(a) risk across the MASLD disease spectrum · Dipeng Li · 2026 · Cites this paper
  6. Cytochrome P450 2E1 deficiency alters hepatic mitochondria and impairs liver organoid formation · 2026 · Related
  7. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study · Matthew James Armstrong · 2015 · 2191 citations · Cited by this paper
  8. Metabolomic signatures of type 2 diabetes and mortality: Methodological considerations and unresolved questions · 2026 · Related
  9. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) · Frank Tacke · 2024 · 2049 citations · Cited by this paper
  10. STAU1 fine-tunes adipose thermogenesis by regulating Ucp1 mRNA stability · 2026 · Related
  11. Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease · Robert C. Clarke · 2009 · 1694 citations · Cited by this paper
  12. Gut-liver metabolic and enterohormonal remodeling drives progression from metabolic dysfunction-associated steatotic liver disease to steatohepatitis · 2026 · Related
  13. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review · Wah‐Kheong Chan · 2023 · 761 citations · Cited by this paper
  14. The endogenous ghrelin antagonist, LEAP2, accelerates puberty onset in conditions of early obesity · 2026 · Related
  15. Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease · Hae‐Ki Min · 2012 · 660 citations · Cited by this paper
  16. Muscle-derived ANXA2 promotes hepatic steatosis by activating SREBP1c-mediated de novo lipogenesis · 2026 · Related
  17. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology · Børge Grønne Nordestgaard · 2016 · 585 citations · Cited by this paper
  18. The effects of acute ketone monoester supplementation on brain insulin responsiveness and cognitive performance: Results of a randomized, double-blind, placebo-controlled crossover trial in older men with overweight · 2026 · Related
  19. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States · Zobair M. Younossi · 2020 · 583 citations · Cited by this paper
  20. SGLT2 inhibitors and GLP-1 receptor agonists in atrial fibrillation treatment: Clinical evidence and mechanistic insights · 2026 · Related
  21. Comparison of CT Methods for Determining the Fat Content of the Liver · Yoshihisa Kodama · 2007 · 517 citations · Cited by this paper
  22. Data leakage and overadjustment bias in proteomic prediction models of mortality among cardiovascular-kidney-metabolic syndrome stage 0–3 · 2026 · Related
  23. Lipoprotein (a) measurements for clinical application · Santica M. Marcovina · 2015 · 338 citations · Cited by this paper
  24. Lipoprotein(a) and cardiovascular disease · Børge Grønne Nordestgaard · 2024 · 281 citations · Cited by this paper
  25. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a) · Steven E. Nissen · 2023 · 230 citations · Cited by this paper
  26. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease · Eberhard Roeseler · 2016 · 227 citations · Cited by this paper
  27. Computed Tomography Scans in the Evaluation of Fatty Liver Disease in a Population Based Study · Irfan Zeb · 2012 · 225 citations · Cited by this paper
  28. Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States · Stephen A. Varvel · 2016 · 220 citations · Cited by this paper
  29. Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population · Pia R. Kamstrup · 2015 · 206 citations · Cited by this paper
  30. Non-genetic influences on lipoprotein(a) concentrations · Byambaa Enkhmaa · 2022 · 194 citations · Cited by this paper
  31. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention · Frank Tacke · 2021 · 154 citations · Cited by this paper
  32. Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial · Yumie Takeshita · 2022 · 122 citations · Cited by this paper
  33. Computed tomography attenuation values in fatty liver · Graeme M. Bydder · 1981 · 114 citations · Cited by this paper
  34. Lipoprotein(a) in cirrhosis. · John Feely · 1992 · 113 citations · Cited by this paper
  35. Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease · Nandini M. Meyersohn · 2020 · 106 citations · Cited by this paper
  36. Lp(a) [Lipoprotein(a)]-Related Risk of Heart Failure Is Evident in Whites but Not in Other Racial/Ethnic Groups · Brian T. Steffen · 2018 · 69 citations · Cited by this paper
  37. Lipoprotein (a) and risk for calcification of the coronary arteries, mitral valve, and thoracic aorta: The Multi-Ethnic Study of Atherosclerosis · Parveen K. Garg · 2020 · 62 citations · Cited by this paper
  38. Implication between Genetic Variants from APOA5 and ZPR1 and NAFLD Severity in Patients with Hypertriglyceridemia · Virginia Esteve-Luque · 2021 · 52 citations · Cited by this paper
  39. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor · Kanako Konishi · 2020 · 45 citations · Cited by this paper

Source: OpenAlex (CC0)